Allergy Therapeutics plc
OTC: AGYTF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Manuel Llobet
- Employees
- 612
- Headquarters
- Worthing, United Kingdom
- IPO year
- 2010
- Market cap
- $655.5M
- Website
- https://www.allergytherapeutics.com
Loading AGYTF…
Loading profile data…Frequently asked questions about AGYTF
What does Allergy Therapeutics plc (AGYTF) do?
Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes pres...
Where does AGYTF trade?
Allergy Therapeutics plc (AGYTF) trades on the Other OTC.
What sector is AGYTF in?
Allergy Therapeutics plc (AGYTF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Allergy Therapeutics plc?
Manuel Llobet is the chief executive officer of Allergy Therapeutics plc (AGYTF).
Where is Allergy Therapeutics plc headquartered?
Allergy Therapeutics plc is headquartered in United Kingdom.
Does AGYTF pay a dividend?
Allergy Therapeutics plc (AGYTF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AGYTF go public?
Allergy Therapeutics plc (AGYTF) completed its initial public offering in 2010.